Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

By afschroeder • March 21, 2026

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C, Bardia A. Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. ESMO Open. 2026 Mar 19;11(4):106905. doi: 10.1016/j.esmoop.2026.106905. Epub ahead of print. PMID: 41861751.

Tags: Hematology/Oncology, HR-positive/HER2-negative metastatic breast cancer, metastatic triple-negative breast cancer, Pooled analysis, Publications, Sacituzumab govitecan, safety

Related Posts

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study

LeVee A, Santos B, Wong M, Ruel N, Schmolze D, Kang I, Tsai K, Mortimer J, McArthur H. Predictors of pathologic complete response in early-stage[...]

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H,[...]

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]